Insider trade

Officer sold ~$368K of CORT shares in the open market

Traded Nov 3, 2025 · Filed Nov 6, 2025

Why it stands out

Corcept Therapeutics's See Remarks sold $368K of Corcept Therapeutics shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$368,245

Shares × reported transaction price

Timing vs results

95 days after results of Jul 31, 2025, 1 day before results of Nov 4, 2025

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+2.5%	+0.1%	+2.3%
30 days	+12.6%	+1.9%	+10.7%
90 days	−48.0%	+1.0%	−49.0%
180 days	−29.3%	+9.4%	−38.6%

Past results only. Not a forecast.

The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.47 to $73.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Includes 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.